Pancreatic neuroendocrine carcinoma (PNEC) is a rare, aggressive malignancy with limited therapeutic options and a dismal prognosis, particularly in young patients.
Approximately 85% of PNEC cases eventually progress to metastatic cancer.
Despite advances in oncology, optimal management strategies for metastatic PNEC remain undefined, especially in chemotherapy-ineligible cases.
